BCM
MYGN icon

Bayesian Capital Management’s Myriad Genetics MYGN Stock Holding History

Bayesian Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,400
Closed -$111K – 390
2025
Q3 		$111K Buy
+15,400
New +$91.4K 0.02% 482
2024
Q3 		– Sell
-19,400
Closed -$475K – 927
2024
Q2 		$475K Buy
+19,400
New +$426K 0.05% 387
2018
Q1 		– Sell
-22,800
Closed -$783K – 743
2017
Q4 		$783K Buy
+22,800
New +$769K 0.16% 217
2017
Q3 		– Sell
-23,000
Closed -$594K – 592
2017
Q2 		$594K Sell
23,000
-7,100
-24% -$151K 0.22% 155
2017
Q1 		$578K Buy
+30,100
New +$533K 0.27% 130

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bayesian Capital Management's MYGN Position: Q4 2025 in Review

Bayesian Capital Management sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 15,400 shares — an estimated $111K sold.

Bayesian Capital Management first reported a position in MYGN in Q1 2017 and held it in 5 quarters. The position peaked at $783K in Q4 2017. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

  • Bayesian Capital Management reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 15,400 Myriad Genetics shares in Q4 2025, an estimated $111K.
  • Bayesian Capital Management first reported a position in Myriad Genetics in Q1 2017 and held it in 5 quarters.
  • Bayesian Capital Management's Myriad Genetics position peaked at $783K in Q4 2017.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.